Zobrazeno 1 - 5
of 5
pro vyhledávání: '"dos Santos, VGV"'
Autor:
Vilhena LS; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., de Azevedo da Silva AC; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Dias da Silva DM; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Pinto DP; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Coelho EF; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., de Araújo JFGM; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., da Silveira GPE; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Pereira HM; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., da Silva LSFV; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Estrela Marins RCE; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.; Cidade Universitária da Universidade Federal do Rio de Janeiro, CEP 21941-580, Rio de Janeiro, RJ, Brazil., Bortolini RG; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Souza TML; Center for Technological Development in Health, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Dos Santos VGV; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., de Assis Nascimento V; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Amendoeira FC; Pharmacology Laboratory, Department of Pharmacodynamics and Physiology, National Institute for Quality Assurance in Health, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., da Fonseca LB; Equivalence and Pharmacokinetics Laboratory (SEFAR), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
Publikováno v:
Biomedical chromatography : BMC [Biomed Chromatogr] 2023 May; Vol. 37 (5), pp. e5606. Date of Electronic Publication: 2023 Mar 05.
Autor:
Pauvolid-Corrêa A; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.; Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.; Departamento de Veterinária, Universidade Federal de Viçosa (UFV), Viçosa, MG 36570-900, Brazil., Caetano BC; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Machado AB; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Ferreira MA; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Valente N; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Neves TK; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Geraldo K; Instituto Nacional de Infectologia Evandro Chagas (INI), Fiocruz, Rio de Janeiro, RJ 21040-900, Brazil., Motta F; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Dos Santos VGV; Instituto Nacional de Infectologia Evandro Chagas (INI), Fiocruz, Rio de Janeiro, RJ 21040-900, Brazil., Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas (INI), Fiocruz, Rio de Janeiro, RJ 21040-900, Brazil., Siqueira MM; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Resende PC; Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Publikováno v:
Biology methods & protocols [Biol Methods Protoc] 2022 Aug 22; Vol. 7 (1), pp. bpac021. Date of Electronic Publication: 2022 Aug 22 (Print Publication: 2022).
Autor:
Ackers, M, Alexander, SB, Allen, M, Bakari, M, Barsdorf, N, Barth-Jones, D, Birx, D, Cunningham, CK, DeCock, K, Francis, D, Fuchs, J, Hemelaar, J, Ireland, J, Kapoor, S, Karamov, E, Klein, M, Levendal, E, Lie, R, Macklin, R, Mathieson, B, Mathur, R, Mukengetshibaka, L, Nanvubya, A, Nakwagala, F, Nixon, S, Pantaleo, G, Pitisuttithum, P, Rogers, AS, dos Santos, VGV, Sheets, R, Safrit, J, Smit, T, Thorpe, P, Verlinde, C, Villafana, T, Warren, M, Xu, J, Mhalu, F, Thior, I, Amin, A, Bouesseau, MC, Chang, ML, Henri, M, Kieny, MP, Labelle, S, Malonza, I, Obermeyer, CM, Osmanov, S, Otani, J, Pagliusiuhe, S, Schmid, G, Sigurdson, J, Collins, C, Hankins, C, Thiam, MB, Grp, WHO-UNAIDSE
Publikováno v:
AIDS. 19(17)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::0894c3d5a58d74405141338b27d831b2
http://ora.ox.ac.uk/objects/uuid:7147f6d1-3c05-4412-baf7-ed951f713f05
http://ora.ox.ac.uk/objects/uuid:7147f6d1-3c05-4412-baf7-ed951f713f05
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jorge Casseb
Desde o relato dos primeiros casos da síndrome da imunodeficiência adquirida (Aids) no início da década de 1980, nos Estados Unidos, e o posterior descobrimento de seu agente causal, o vírus da imunodeficiência humana, em 1983, a doença conver
